hotspot -WSS

hotspot

author：Wikipedia 2025-09-03 05:40:09 - browse：263

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： As AI regulations shape up, health tech startups beg for clarity

knowledge

WSS

New CMS data security rules will hurt Medicare, Medicaid research

New CMS data security rules will hurt Medicare, Medicaid research

Home health providers sue Medicare over payment cuts

Researchers tackle phage therapy hurdles for wider adoption

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

Swim instructor mom warns parents not to buy blue swimsuits for kids

knowledge

hotspot

explore

Continuity nursing helped my family in our darkest PICU moments

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

In Memoriam: Notable people who died in 2023

Rikers Island jail violence not addressed, NYC should be held in contempt: Fed monitor

New air purifier tech could be key to improving indoor air quality

Biden’s NIH nominee is languishing in Congress

The cancer drug shortage isn’t new — and neither are the solutions

ACA's risk program benefits Blue Cross Blue Shield insurers

The high cost of giving birth even with insurance

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

hotspot

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

As AI regulations shape up, health tech startups beg for clarity

Weight loss drugs aren’t covered by Obamacare. That may change

Biden declares emergency in flood

Hospitals are piloting generative AI tools as regulators play catch

New study raises questions about niacin and heart health

leisure time

knowledge

hotspot

leisure time